Pediatric Open-Label Extension Study of Etanercept in Patients With Plaque Psoriasis

An Open-Label Extension Study to Evaluate the Safety of Etanercept in Pediatric Subjects With Plaque Psoriasis

The purpose of this study is to evaluate the long-term safety and efficacy of etanercept in pediatric patients with moderate to severe psoriasis.

This study was a multicenter, open-label extension study for pediatric patients who participated in Study 20030211 (NCT00078819).

Inclusion Criteria:

• Enrollment on previous Amgen study 20030211 (NCT00078819)

Exclusion Criteria:

• Serious or clinically significant adverse event on Amgen study 20030211 related to etanercept